Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
25.33
+0.88 (+3.60%)
Streaming Delayed Price
Updated: 3:07 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
374,231
Open
24.62
Bid (Size)
25.33 (1)
Ask (Size)
25.36 (2)
Prev. Close
24.45
Today's Range
23.71 - 25.43
52wk Range
11.25 - 58.38
Shares Outstanding
50,086,978
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
March 20, 2024
From
Abraham, Fruchter & Twersky, LLP
Via
GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 08, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Performance
YTD
+7.88%
+7.88%
1 Month
+5.98%
+5.98%
3 Month
+4.45%
+4.45%
6 Month
-45.95%
-45.95%
1 Year
-33.90%
-33.90%
More News
Read More
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics: Q4 Earnings Insights
February 29, 2024
Via
Benzinga
11 Analysts Have This to Say About Akero Therapeutics
November 14, 2023
Via
Benzinga
Akero Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Via
Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
March 04, 2024
Via
Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
Via
InvestorPlace
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
March 04, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks Whale Activity In Today's Session
February 29, 2024
Via
Benzinga
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
February 29, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Akero Therapeutics Inc.
Via
GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
Via
Investor's Business Daily
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Via
Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
February 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.